Luciole Medical AG

Luciole Medical AG is a company focused on developing advanced cerebral monitoring solutions to improve brain health and patient outcomes through innovative technology. Founded in 2007 in Zurich, Switzerland, Luciole Medical AG specializes in cerebral monitoring solutions. The company raised CHF 5. 3 million in Series A funding on September 17, 2018, led by Credit Suisse Entrepreneur Capital, with participation from BOV Capital, Zürcher Kantonalbank, b2venture, and investiere.

The founders, Cassandra Tighe and Emanuela Keller, have a history in healthcare innovation. Luciole Medical AG specializes in advanced cerebral monitoring solutions designed to enhance brain health. Their core product offerings include a proprietary monitoring platform that integrates innovative technologies such as patches and probes. These devices are engineered to provide real-time data on cerebral activity, aiming to address critical medical needs related to neurological conditions.

The end use cases for these products focus on improving patient outcomes through enhanced monitoring capabilities in clinical settings. Luciole Medical AG serves a diverse clientele, including hospitals, neurological research institutions, and healthcare providers, primarily targeting markets in Europe, North America, and select regions in Asia. Luciole Medical AG generates revenue through a structured model that includes partnerships with healthcare providers and institutions. The company engages in B2B transactions, supplying its monitoring products directly to hospitals and clinics that require advanced cerebral assessment tools.

This model enables Luciole Medical AG to establish long-term relationships with its clients, facilitating ongoing support and updates for their products. While specific pricing plans for individual products or services have not been disclosed, it is anticipated that the revenue structure includes both one-time purchases and potential subscription-based services for ongoing monitoring solutions, enhancing the overall value proposition for end users in the healthcare sector. Luciole Medical AG plans to utilize the CHF 5. 3 million raised in Series A funding to support the development of new products aimed at expanding their cerebral monitoring capabilities.

The company is targeting expansion into specific markets in Asia, with plans to establish a presence by 2022. This funding will also facilitate enhancements to their existing product line, ensuring they meet the evolving needs of their healthcare clients.